{"analyses":[{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.74","estimateComment":"Reference level = placebo arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.49","statisticalComment":"One-sided test","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"17.2","value":"13.4"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"8.6","value":"5.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"384"}],"units":"Participants"}],"description":"Prostate cancer death rates were estimated by the cumulative incidence method, with failure defined as death due to prostate cancer or complications of protocol treatment (centrally reviewed), death with known progressive metastatic disease while on salvage hormone therapy, or death with a known rising PSA while on salvage hormone therapy. Patients alive at time of analysis were censored. Any other death was treated as a competing risk. Four-year follow-up was required of all patients, but twelve-year rates were reported. Patients are followed until death. \"Prostate cancer death\" is a more accurate wording for the protocol endpoint of \"disease-specific survival\", and matches the protocol definition.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (64.8 Gy) + placebo (daily 2 years)","id":"OG000","title":"Placebo"},{"description":"Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years)","id":"OG001","title":"Bicalutamide"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"From date of randomization to 12 years.","title":"Prostate Cancer Death (12-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}